TW202327650A - 治療多發性骨髓瘤之方法 - Google Patents

治療多發性骨髓瘤之方法 Download PDF

Info

Publication number
TW202327650A
TW202327650A TW111135302A TW111135302A TW202327650A TW 202327650 A TW202327650 A TW 202327650A TW 111135302 A TW111135302 A TW 111135302A TW 111135302 A TW111135302 A TW 111135302A TW 202327650 A TW202327650 A TW 202327650A
Authority
TW
Taiwan
Prior art keywords
antigen
antibody
day
months
binding fragment
Prior art date
Application number
TW111135302A
Other languages
English (en)
Chinese (zh)
Inventor
菲尼克斯 何
艾普斯 希瑟 艾倫 凡
瑪麗 坎貝爾
艾咪 金
新太 陳
陶德 席拉爾
Original Assignee
美商思進公司
美商斯普林渥克斯治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商思進公司, 美商斯普林渥克斯治療有限公司 filed Critical 美商思進公司
Publication of TW202327650A publication Critical patent/TW202327650A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111135302A 2021-09-23 2022-09-19 治療多發性骨髓瘤之方法 TW202327650A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163247637P 2021-09-23 2021-09-23
US63/247,637 2021-09-23

Publications (1)

Publication Number Publication Date
TW202327650A true TW202327650A (zh) 2023-07-16

Family

ID=83996580

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111135302A TW202327650A (zh) 2021-09-23 2022-09-19 治療多發性骨髓瘤之方法

Country Status (6)

Country Link
US (1) US20240343819A1 (enExample)
EP (1) EP4405393A1 (enExample)
JP (1) JP2024534602A (enExample)
CA (1) CA3232799A1 (enExample)
TW (1) TW202327650A (enExample)
WO (1) WO2023049694A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
IL316750A (en) 2022-05-20 2025-01-01 Springworks Therapeutics Inc Treatments with Nirogesstat
US12667555B2 (en) 2022-05-20 2026-06-30 Springworks Therapeutics, Inc. Treatment of ovarian cancer with nirogacestat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
AU2024390850A1 (en) * 2023-12-01 2026-04-02 Teneoone, Inc. Methods for the treatment of multiple myeloma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
MA44254A (fr) 2016-02-17 2018-12-26 Seattle Genetics Inc Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
MX2021012407A (es) * 2019-04-10 2021-11-12 Glaxosmithkline Ip Dev Ltd Terapia de combinacion con un anticuerpo anti bcma y un inhibidor de gamma secretasa.

Also Published As

Publication number Publication date
WO2023049694A1 (en) 2023-03-30
US20240343819A1 (en) 2024-10-17
JP2024534602A (ja) 2024-09-20
EP4405393A1 (en) 2024-07-31
CA3232799A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
US20250387476A1 (en) Methods of Treating Cancer
JP7573062B2 (ja) がん治療における化学療法剤と組み合わせた抗ｆｇｆｒ２抗体
JP6963577B2 (ja) 抗シグレック−８抗体およびその使用の方法
WO2023049694A1 (en) Methods of treating multiple myeloma
JP2022516881A (ja) 抗ｃｔｌａ４抗体およびその使用方法
EP3816290A1 (en) Antibody binding to cell adhesion molecule 3
TW202202170A (zh) 治療多發性骨髓瘤之方法
JP7350756B2 (ja) 抗ヒトｐｄ－ｌ２抗体
JP2022518399A (ja) Ｐｄ－１軸結合アンタゴニスト及びｒｎａワクチンを用いてがんを処置する方法
EP3252077A1 (en) Superior efficacy of cd37 antibodies in cll blood samples
JP7034911B2 (ja) 全身性肥満細胞症を処置するための方法および組成物
US20220306743A1 (en) Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
KR20210025023A (ko) 콘드로이틴 황산 프로테오글리칸-5에 결합하는 항체
TW202340243A (zh) 抗ｃｄ３９抗體及其用途
US20250313631A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
US20240239912A1 (en) Targeted reduction of activated immune cells
EP3211080B1 (en) Anti human gas6 monoclonal antibodies
US20220340662A1 (en) Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
HK40128024A (zh) 双特异性抗egfr/c-met抗体和抗pd-1抗体的组合疗法
TW202540161A (zh) 治療骨髓增生性腫瘤之方法
WO2026078647A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma
HK40085355A (en) Methods of treating multiple myeloma